LianBio, a Princeton-based biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, announced Wednesday that Dr. Debra Yu has resigned as president and chief strategy officer to pursue other opportunities.
The move is effective Jan. 1, 2023.
In order to facilitate her transition, Yu entered into a consulting agreement with LianBio effective Jan. 1 through June 30, 2023.
Yu joined the company when LianBio was first established in 2019. She has been a valued member of LianBio’s executive team and an integral part of LianBio’s transformation from an early-stage startup into a late clinical stage biotechnology company.
“We thank Debra for her many contributions to LianBio, and recognize the legacy she leaves behind,” CEO Yizhe Wang said.
“The LianBio team wishes her the best in all her future endeavors. Since our founding, we have made significant progress advancing our mission to bring innovative medicines to patients in China. The strong foundation Debra helped build positions LianBio well for continued success.”
